SCHEMBL875324

SCHEMBL875324

C=C(C)C(=O)OCCSSc1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
EHMT2 Q96KQ7 1/20 0.42
EHMT1 Q9H9B1 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
ALDH1A1 P00352 5/20 0.41
HDAC1 Q13547 5/20 0.40
HDAC2 Q92769 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30175601 1.00 LMNA (0.44) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL17253259 0.87 LMNA (0.47) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL15777571 0.84 EHMT2 (0.48) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL14059363 0.83 LMNA (0.56) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL30613337 0.83 THRB (0.40) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL31040491 0.83 ALDH1A1 (0.49) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL31040490 0.83 ALDH1A1 (0.49) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL844408 0.83 EHMT2 (0.47) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL903346 0.83 ALDH1A1 (0.49) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL20095020 0.82 LMNA (0.45) LMNAEHMT2EHMT1APOBEC3GALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109666121-B Hybrid dynamic cross-linked polymer and application thereof 厦门逍扬运动科技有限公司 2023-09-22 CN claimed
US-20160206750-A1 BLOCK COPOLYMERS ROIVANT SCIENCES LTD. (GB) 2016-07-21 US claimed
EP-3247328-B1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS GENEVANT SCIENCES GMBH (CH) 2026-01-07 EP disclosed
US-20250276000-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS GENEVANT SCIENCES GMBH (CH) 2025-09-04 US disclosed
US-20250186599-A1 BLOCK COPOLYMERS GENEVANT SCIENCES GMBH (CH) 2025-06-12 US disclosed
US-20240325552-A1 BLOCK COPOLYMERS GENEVANT SCIENCES GMBH (CH) 2024-10-03 US disclosed
US-11938191-B2 Block copolymers GENEVANT SCIENCES GMBH (CH) 2024-03-26 US disclosed
CN-116964228-A Composition and method for waterproofing leather 斯塔尔国际有限公司 2023-10-27 CN disclosed
CN-116903512-A De-glu-insulin intermediate and preparation method of de-glu-insulin 浙江湃肽生物股份有限公司深圳分公司 2023-10-20 CN disclosed
CN-109666121-B Hybrid dynamic cross-linked polymer and application thereof 厦门逍扬运动科技有限公司 2023-09-22 CN disclosed
US-20230135432-A1 POLYMERIC NANOPARTICLES AND DERIVATIVES THEREOF FOR NUCLEIC ACID BINDING AND DELIVERY UNIV MASSACHUSETTS (US) 2023-05-04 US disclosed
WO-2012039855-A1 PH-SENSITIVE COMPOSITIONS FOR DELIVERY OF BETA LAPACHONE AND METHODS OF USE THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-03-29 WO disclosed
US-20110286957-A1 MULTIBLOCK COPOLYMERS PHASERX, INC. (US) 2011-11-24 US disclosed
EP-2364330-A2 MULTIBLOCK COPOLYMERS University Of Washington (US) 2011-09-14 EP disclosed
WO-2011062965-A2 TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2011-05-26 WO disclosed
WO-2011060281-A1 HYDROPHOBIC BLOCK CONJUGATED THERAPEUTIC AGENTS UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2011-05-19 WO disclosed
US-20100234565-A1 MOLECULARLY IMPRINTED POLYMERS FOR THE RECOGNITION OF GLUTATHIONE GSH, METHODS FOR PREPARING SAME AND USES THEREOF POLYINTELL (FR) 2010-09-16 US disclosed
US-20100234565-A1 MOLECULARLY IMPRINTED POLYMERS FOR THE RECOGNITION OF GLUTATHIONE GSH, METHODS FOR PREPARING SAME AND USES THEREOF POLYINTELL (FR) 2010-09-16 US disclosed
WO-2010054266-A2 MULTIBLOCK COPOLYMERS UNIVERSITY OF WASHINGTON (US) 2010-05-14 WO disclosed
WO-2009056716-A1 MOLECULARLY IMPRINTED POLYMERS FOR THE RECOGNITION OF GLUTATHIONE GSH, METHODS FOR PREPARING SAME AND USES THEREOF POLYINTELL (FR) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186599-A1 BLOCK COPOLYMERS CHMP4B, CD47, EEA1 LMNA 1251/4885EHMT2 4383/4885EHMT1 4540/4885
US-20250276000-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS CD63, LIPA, NPC1L1 LMNA 146/4885EHMT2 4251/4885EHMT1 4421/4885
US-11938191-B2 Block copolymers CHMP4B, CD47, EEA1 LMNA 1251/4885EHMT2 4383/4885EHMT1 4540/4885
US-20240325552-A1 BLOCK COPOLYMERS CHMP4B, CD47, EEA1 LMNA 1251/4885EHMT2 4383/4885EHMT1 4540/4885
US-20110286957-A1 MULTIBLOCK COPOLYMERS ABCB4, CD47, MCL1 LMNA 1530/4885EHMT2 3236/4885EHMT1 3595/4885
US-20160206750-A1 BLOCK COPOLYMERS CHMP4B, CD47, EEA1 LMNA 1251/4885EHMT2 4383/4885EHMT1 4540/4885
US-20230135432-A1 POLYMERIC NANOPARTICLES AND DERIVATIVES THEREOF FOR NUCLEIC ACID BINDING AND DELIVERY SNRPE, HNRNPAB, MTREX LMNA 125/4885EHMT2 3258/4885EHMT1 3540/4885
US-20100234565-A1 MOLECULARLY IMPRINTED POLYMERS FOR THE RECOGNITION OF GLUTATHIONE GSH, METHODS FOR PREPARING SAME AND USES THEREOF GSTM2, GSTP1, GSTM1 LMNA 4844/4885EHMT2 135/4885EHMT1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.